SHCBP1 is a novel target and exhibits tumor‑promoting effects in gastric cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• SHC SH2 domain-binding protein 1 (SHCBP1) is implicated in cell proliferation and cycle progression.
• The specific role of SHCBP1 in gastric cancer (GC) pathogenesis is not well understood.

Purpose of the Study:

• To investigate the expression and functional role of SHCBP1 in gastric cancer.
• To elucidate the molecular mechanisms by which SHCBP1 influences GC cell behavior.

Main Methods:

• Analysis of SHCBP1 expression in GC tissues and cell lines using TCGA database and cell line experiments.
• Assessment of SHCBP1's impact on GC cell proliferation, cell cycle, and apoptosis.
• Investigation of the association between SHCBP1 and key cell cycle regulators (CDK4, cyclin D1) and apoptosis-related proteins (caspase-3, PARP).
• Evaluation of SHCBP1's effect on tumor cell invasion and metastasis.

Main Results:

• SHCBP1 is significantly upregulated in GC tissues and cell lines (MGC-803, SGC-7901).
• Downregulation of SHCBP1 inhibited GC cell proliferation, promoted cell cycle arrest, and induced apoptosis.
• SHCBP1 promotes cell cycle progression via the CDK4-cyclin D1 pathway.
• SHCBP1 suppresses caspase-3 and caspase PARP-dependent apoptosis.
• SHCBP1 enhances tumor cell invasion and metastasis, indicating promotion of tumor growth.

Conclusions:

• SHCBP1 acts as an oncogene in gastric cancer by promoting proliferation, cell cycle progression, and inhibiting apoptosis.
• SHCBP1 influences GC progression through the CDK4-cyclin D1 and caspase signaling pathways.
• SHCBP1 represents a potential diagnostic marker and therapeutic target for gastric cancer.